RE: RE: RE: Losts its mojo todayThe NR states the problem clearly - they can't get timely assays.
When the results come, certainly before the planned "mid-year" PEA, the stock will run like a turpentined cat.
IMHO.
That's why I remain over-weighted, with a cost base, according to my Stockwatch accounting, of minus $16.49/share.